Owkin iconOwkin

AI biology company whose K Pro agent answers drug discovery questions on targets, biomarkers and druggability using multimodal patient data

25M Patients in Data Network (claim)
840 Partner Hospitals (claim)
2016 Founded

Overview

Owkin says it is building "the first solution that automates AI in biology". Its main product, K Pro, is a multi-agent "AI scientist" for pharma R&D: researchers ask plain-language questions about target prioritization, druggability and biomarkers, an orchestrator picks the right skills, and K Pro answers from public data, Owkin's MOSAIC multimodal dataset and its patient data network (25 million patients across 840 hospitals, per Owkin). K Pro launched as an agentic co-pilot in October 2025; in 2026 AstraZeneca, Sanofi and Servier signed K Pro license deals, and Owkin's Pathology Explorer agent launched with Anthropic's Claude for Healthcare and Life Sciences. Owkin itself says K Pro outputs are hypotheses that need expert review. The company was founded in Paris in 2016 by Thomas Clozel (CEO) and Gilles Wainrib.

The Verdict

Who Should Use Owkin?

Best For

  • Biopharma teams prioritizing oncology targets and biomarkers
  • Researchers who want to query multimodal patient data in plain language
  • Scientists who want to try an AI biology agent free on public datasets

Not Ideal For

  • Clinicians looking for a diagnostic tool at the bedside
  • Teams that need peer-reviewed validation before relying on AI hypotheses

What's Great

  • Free tier lets anyone try K Pro on 19 public datasets
  • Large pharma licensees: AstraZeneca, Sanofi, Servier
  • Proprietary multimodal data (MOSAIC) on the professional tier

Watch Out For

  • Outputs are hypotheses that need expert review, per Owkin's own FAQ
  • Free tier cannot upload data or use proprietary datasets
  • No published prices and few independent user reviews

Pricing

View all features & details

K Pro

  • Plain-language questions on targets, druggability, biomarkers
  • Orchestrator agent that selects skills
  • Generates research reports
  • MOSAIC multimodal dataset (professional tier)

Milestones

  • K Pro launched as agentic co-pilot (Oct 2025)
  • Pathology Explorer agent with Claude for Healthcare and Life Sciences (Jan 2026)
  • K Pro licenses: AstraZeneca, Sanofi, Servier (2026)

How It Compares

Feature Owkin Tempus AI
Main AI product K Pro AI scientist Tempus One clinical assistant
Primary users Biopharma R&D Oncologists, pharma
Free tier Yes (public datasets) No public free tier
Own lab testing No Yes

Sources: Owkin · Pathology Explorer (Jan 2026) · The Pharma Letter

Is this your tool? Add a badge